Abstract
Therapy‐triggered autoimmunity and inflammation in many cancer patients, as well as treatment costs, hamper the success of cancer immunotherapy. The study by Pfeiffer et al in this issue of EMBO Molecular Medicine constitutes a clear step towards a more simple, scalable and affordable approach in generating in situ T cells reprogrammed with chimeric antigen receptors (CARs) (Pfeiffer et al , 2018).
Highlights
Therapy-triggered autoimmunity and inflammation in many cancer patients, as well as treatment costs, hamper the success of cancer immunotherapy
The first real therapeutic success of immunotherapy in cancer was the use of antibodies targeted to cancer cells, which harnessed the immune response to help deliver their therapeutic effect, such as rituximab based on Fc engagement (Mellor et al, 2013), or trastuzumab (Carter et al, 1992) based on FcR
Might there be cheaper alternatives? Yes, the knowledge gained from the clinical success of chimeric antigen receptors (CARs)-T cells has enabled others to try to simplify and mimic the process, without the costly patient-specific therapy or extra-corporeal engineering
Summary
Therapy-triggered autoimmunity and inflammation in many cancer patients, as well as treatment costs, hamper the success of cancer immunotherapy. The existence of immune responses to human cancer is nowadays well established (reviewed in Miller & Sadelain, 2015), and immunotherapy has become an increasingly important part of cancer medical care.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
